The GlobalCarotid Artery Disease Market Forecast 2027 is expected to register a CAGR of 4.1% to reach USD 11,621.6 million.

Market Dynamics

Carotid artery disease is a condition in which plaques are developed in the arteries that supply blood to the brain, which often lead to strokes. The prominent factors that drive the market growth are increasing geriatric population, increasing adoption of an unhealthy lifestyle, and the popularity of over-the-counter (OTD) drugs. However, the high cost of diagnostics and surgeries and stringent government regulations for the carotid artery disease are likely to restrain market growth over the forecast period.

Carotid arteries are blood vessels in the neck that supply oxygen-rich blood to the brain. These vessels could get blocked by plaque, a fatty substance consisting of cholesterol, calcium, and other materials. Medication helps to reduce plaque build-up in carotid arteries and blood vessels throughout the body. Ardent efforts by manufacturers of therapeutic drugs for the treatment of carotid artery disease have aided the growth of the global carotid artery disease market. Medications often prescribed for carotid artery disease are antiplatelet medications, anticoagulant medications, tissue plasminogen activator (tPA). The most commonly used anti-platelet medication is aspirin. Other drugs include clopidogrel (Plavix) and dipyridamole (Persantine), which may be prescribed alone or in combination with aspirin to reduce the risk of stroke. This factor is expected to lead to the growth of the global carotid artery disease market and may even increase the revenue-generation ability of market players. The current first line of treatment for carotid artery disease includes anti-platelets medication and tissue plasminogen activator (tPA). The increasing demand for over-the-counter drugs by the patient population is boosting the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6301 

Segment analysis

The global carotid artery disease market by treatment & diagnosis is segmented into treatment and diagnosis. The treatment is segmented into medications and surgical procedures. The medications are further segmented into cholesterol-lowering statins, antiplatelet drugs, and antihypertensive drugs. The surgical procedures are further segmented into carotid endarterectomy, carotid artery angioplasty & stenting, and carotid artery bypass.

The global carotid artery disease market by end user is segmented into hospital & clinics, ambulatory surgical centers, pharmacies, and others.

Regional Analysis

On the basis of region, the global carotid artery disease market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. Rise in prevalence of cardiovascular disorders, increase in disorders such as ischemic stroke, peripheral vascular lesions, growth in geriatric population, technological advancement, and a surge in adoption rates of minimally invasive surgeries. However, factors such as complications associated with stents and stringent regulations related to approval processes restrain market growth. Furthermore, the development of biocompatible stents and rise in the emergence of carotid artery stents with new technology drive the market growth during the forecast period.

North America is expected to dominate the market. According to the Healthmetrics Health Organization, stroke is a leading cause of serious long-term disability in the US, and each year, about 795,000 people experience a new or recurrent stroke. Approximately, 610,000 of these are first attacks, and 185,000 are recurrent attacks.

Europe currently holds a significant share in the global carotid artery disease market. According to European Heart Network, each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

Asia-Pacific is the fastest growing region in the global carotid artery disease market owing to developing economies of China, India, and South Korea, which are emerging as major destinations for outsourcing clinical trials, drug manufacturing, and pathology testing.

The Middle East and Africa market is projected to hold the least share in the global carotid artery disease market. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others.

Key Findings of the Study:

• Global carotid artery disease market is projected to reach over 11,621.6 million by 2023 with 4.1% CAGR during the review period of 2018 to 2023
• The Americas accounted for the largest share due to the presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the carotid artery disease market in America.
• The treatment & diagnosis segment by treatment is projected to value 8,899.3 million by 2023.
• Some of the additional players operating in the carotid artery disease market are Johnson & Johnson, MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, InspireMD, Impulse Dynamics and AstraZeneca PLC.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/carotid-artery-disease-market-6301